Articles On Antisense Therapeutics (ASX:ANP)

Antisense Therapeutics (ASX:ANP) has announced it is exploring clinical development opportunities for ATL1102 in other indications where inflammation plays a key role in disease progression.

The company is developing and commercialising antisense pharmaceuticals for large unmet markets. Antisense therapy is a form of treatment for genetic disorders or infections.

After the success of its Phase II clinical trial in treating patients with DMD, Antisense Therapeutics (ANP) is actively exploring clinical development in other areas Antisense is now consulting with clinical experts to work out the next...

Following recently reported positive clinical trial results relating to its research into Duchenne Muscular Dystrophy, biopharmaceutical drug development company Antisense Therapeutics (ASX: ANP) has declared that it’s now actively explorin...

As global authorities race to contain the outbreak of coronavirus, Aussie healthcare stock Biotron (ASX:BIT) thinks it may be able to help. The company’s primary focus is anti-virus medications for HIV and Hepatitis B, via the development o...

Also presenting at the CEO Sessions will be Great Boulder Resources, Recce Pharmaceuticals and Antisense Therapeutics.

The biopharmaceutical company will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

Biopharmaceutical company Antisense Therapeutics (ANP) has raised $5.5 million via an options exercise The funds will be used for the Phase 2b clinical trial of the company’s therapy for Duchenne Muscular Dystrophy CEO Mark Diamond than...

The company recently completed successful dosing of patients in the Phase II clinical trial of its antisense inhibitor ATL1102 in DMD (Duchenne muscular dystrophy).

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

The share market bull run stalled just short of record levels this morning as developments in the Westpac scandal knocked the wind out of the big banks. The ASX 200 inched past last month’s record close of 6864, but never threatened the...

Antisense Therapeutics (ANP) has received data from all nine participants having completed the trial for ATL1102 in DMD The phase II trial affirmed the drugs excellent safety profile and positive drug effects on disease progression endpoi...

Data from a Phase 2 clinical trial by Antisense Therapeutics (ASX: ANP) on the immunomodulatory therapy ATL1102 for Duchenne muscular dystrophy has confirmed the drug can have positive effects on progression of the disease. The trial aimed...

Antisense Therapeutics (ASX:ANP) jumped over 20 per cent this morning on news its ATL1102 drug, fighting Duchenne Muscular Dystrophy (DMD), delivered strong preliminary results in its clinical trial. The stock is now up 270 per cent over th...

New Hope Corporation (NHC), Orocobre (ORE), Antisense Therapeutics (ANP), SomnoMed (SOM), Orica (ORI), Karoon Energy (KAR) and TPG Telecom (TPM).

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Antisense Therapeutics (ASX:ANP) has announced the presentation of additional data from seven patients who have completed their 24 weeks of dosing in the ATL1102 phase 2 DMD clinical trial.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

On Stockhead today: the three biggest opportunities for digital transformation in pharma, why it’s time to get excited about cobalt again, the top 10 stocks that doubled (and even tripled) in 24 hours and the stocks investors are shorting r...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Got 90 seconds? Then listen to managing director and CEO Mark Diamond tell us about Antisense Therapeutics. Antisense (ASX:ANP) is an Australian biopharma drug discovery and development company focused on creating, developing and commercial...

Do you know that on this day in 1970 the great American rock guitarist, singer, and songwriter Jimi Hendrix passed away. James Marshall 'Jimi' Hendrix’s mainstream career lasted only four years, but he is widely regarded as one of the most...

Antisense Therapeutics (ASX:ANP) has announced that a review of preliminary data from the six patients who have completed their 24 weeks of dosing in the phase 2 clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne M...

On Stockhead today, the gold M&A just keeps rolling with Azumah the latest takeover target, SRJ reveals why it thinks Oz is a good place for it to list and the industry that billionaire investor Stephen Schwarzman sees as having ‘Amazon...

The best-performing health or biotech company in the past fortnight is… an energy company? BPH Energy (ASX:BPH) describes itself as a diversified business holding investments in biotechnology and resources. In late August, it decided to dip...

Biopharmaceutical drug discovery and development small-cap Antisense Therapeutics Ltd [ASX:ANP] have seen a substantial spike in their share price today, up 89.36%. The post Antisense Therapeutics Share Price Soars 89% with Positive Trial R...

A preliminary review of a Phase II clinical trial involving an immunomodulatory therapy drug developed by Antisense Therapeutics (ASX: ANP) has shown a positive effect for patients with non-amubulant Duchenne muscular dystrophy. The review...

Antisense Therapeutics (ASX:ANP) says it has received confirmation of two of the three proposed Scientific Advice meetings for its planned interactions with regulatory authorities to progress the design and conduct of the next clini...

In this piece of writing, we would discuss the three stocks from healthcare sector traded on the ASX. The Australian benchmark index S&P/ASX 200 closed at 6793.4, down by 24.60 points or 0.4% from the previous close, on 26 July 2019. Ov...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

Antisense Therapeutics (ASX:ANP) has announced that five patients have completed their 24 weeks of dosing in the phase 2 clinical trial of the company's immunomodulatory therapy, ATL1102, for Duchenne Muscular Dystrophy.